Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human

Main objective:

Through blood drug concentration testing, evaluate the post-meal pharmacokinetic characteristics of the curcumin product compared to similar products, and assess the differences in body exposure between the self-developed product and the control product in healthy trial participants.

Secondary objective:

Observe the safety of the self-developed product and the control product in healthy trial participants.

Study population:

Healthy male individuals or non-pregnant non-lactating females

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy
• Intervention / Treatment: Dietary supplement: Nanocurcumin; Dietary supplement: Curcumin

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Qiyue Liu; Phone Number: 86-15952401034; Email: qiyue.liu@cxpharma.com
• Study Contact Backup: Name: Lu Ye; Phone Number: 86-13950049562; Email: lbe_yl@accube.cn

Study Locations

• China
  • Fujian
    • Xiamen, Fujian, China, 361022
      • No. 55, Zhenhai Road
      • Contact: Xi Luo; Phone Number: 86-18359710335; Email: luoxi2999@163.com
      • Contact: Jianfeng Liu; Phone Number: 86-13860426695; Email: liujf5781@sina.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Both men and women are eligible; women must be non-pregnant and non-lactating.
2. Healthy trial participants aged 18 to 65 years (inclusive of the threshold value).
3. Body Mass Index (BMI) = weight (kg) / height² (m²), with BMI within the range of 18.5 to 30.0 kg/m² (including the threshold value); male trial participants must have a weight of ≥ 50.0 kg, and female trial participants must have a weight of ≥ 45.0 kg.
4. Voluntary participants who have signed the informed consent form; the process of obtaining the informed consent form complies with GCP.
5. Female trial participants agree to use effective non-pharmacological methods for appropriate contraception 2 weeks before the trial diet (for male trial participants, starting from the first trial diet), and within 3 months after the last trial diet, and have no plans for egg donation (male sperm donation).

Exclusion Criteria:

1. Select those who have abnormal and clinically significant findings in physical examination, vital sign examination, blood routine, blood biochemistry, coagulation function, blood pregnancy test (only for females), urine routine, 12-lead electrocardiogram, HBsAg, HCV antibody, HIV antibody, syphilis screening, etc.;
2. Those with a history of serious diseases in cardiovascular, endocrine, digestive, respiratory, urinary, immune system and nervous system, or those who developed the above-mentioned diseases during the screening period, and whose research doctors consider them unsuitable to participate in the clinical trial;
3. Those who are allergic to two or more drugs or foods (including lactose-intolerant individuals); or those who are prone to asthma, rash, urticaria, etc.; or those who have a known history of allergy to curcumin or any excipients;
4. Those with a history of mental illness, drug abuse history, or drug dependence history;
5. Those who have used any prescription drugs, over-the-counter drugs, herbal medicine or health supplements within 14 days before the first trial meal (excluding topical preparations or local drug preparations);
6. Those who have smoked an average of more than 5 cigarettes per day within the previous 3 months;
7. Those who have difficulty in blood collection or cannot tolerate venipuncture blood collection;
8. Those who have a history of heavy drinking (more than 14 units of alcohol per day, 1 unit = 360 mL beer or 45 mL 40% spirituous alcohol or 150 mL wine) or who do not agree to stop consuming alcoholic products during the trial period (from the screening day to the last cycle discharge);
9. Those who have used drugs within the previous 3 months, or those with a positive drug abuse screening result;
10. Those who have consumed excessive tea, coffee or caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) every day within the previous 3 months;
11. Those who have donated blood or suffered massive blood loss (more than 200 mL) within the previous 3 months;
12. Those who participated in any drug clinical trial and used any clinical trial drugs within the previous 3 months;
13. Those with special dietary requirements and cannot follow the unified diet;
14. Those who have taken special diets or other diets that affect drug absorption, distribution, metabolism, and excretion factors within 7 days before the first trial meal;
15. Those who have had acute diseases during the screening stage or before the allocation of the trial number;
16. Those whose alcohol breath test result is not 0 mg/100 mL within the first cycle;
17. Those who voluntarily withdraw from the trial;
18. Those judged by the researchers to be unsuitable to participate;
19. The number of participants has reached the limit and the screening number of this trial participant is at the rear.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nano Curcumin Capsules; Test Group	Dietary supplement: Nanocurcumin; In the first cycle, take 2 capsules (250mg each) of the control product (R, Curcumin Capsules). In the second cycle, take 4 capsules (125mg each) of the self-developed product (T, Nano Curcumin Capsules). Take with 240 mL of water and the cleansing period is 7 days.
Active Comparator: Curcumin Capsules; Reference Group	Dietary supplement: Curcumin; In the first cycle, take 4 capsules of the self-developed product (T, Nano Curcumin Capsules) (125 mg per capsule), in the second cycle take 2 capsules of the control product (R, Curcumin Capsules) (250 mg per capsule), take with 240 mL of water, and the cleansing period is 7 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak Plasma Concentration (Cmax)	Evaluation of Peak Plasma Concentration (Cmax)	2 weeks
Area under the plasma concentration versus time curve (AUC) 0-t	plasma concentration-time curve from zero to the time of the last measurable time point t	2 weeks
Area under the plasma concentration versus time curve (AUC)0-∞	area under the plasma concentration-time curve from zero to infinity	2 weeks

Collaborators and Investigators

• Sponsor: Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): January 28, 2026
• Primary Completion (Estimated): February 7, 2026
• Study Completion (Estimated): February 28, 2026

Study Registration Dates

• First Submitted: January 23, 2026
• First Submitted That Met QC Criteria: January 23, 2026
• First Posted (Actual): January 30, 2026

Study Record Updates

• Last Update Posted (Actual): January 30, 2026
• Last Update Submitted That Met QC Criteria: January 23, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: curcumin
• Additional Relevant MeSH Terms: Organic Chemicals; Hydrocarbons, Acyclic; Hydrocarbons; Hydrocarbons, Cyclic; Hydrocarbons, Aromatic; Diarylheptanoids; Heptanes; Alkanes; Catechols; Phenols; Benzene Derivatives; Curcumin; nanocurcumin
• Other Study ID Numbers: [2026]Ethical Audit No. (001)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No